| Literature DB >> 23251287 |
Yu Han1, Ling Zhao, Zhenyu Jiang, Ning Ma.
Abstract
The aim of this study was to investigate the expression of the human leukocyte antigen (HLA)-Cw and killer cell immunoglobulin-like receptor (KIR) genes in a Jilin Han population and to provide a theoretical basis for further studies of their roles in disease. A total of 154 unpaid Jilin Han blood donors were selected and KIR and HLA-Cw genotyping was performed using PCR-SSP. Recognition of HLA-Cw and the corresponding activatory or inhibitory KIR receptor was distinguished according to the identification of HLA-Cw and KIR. In the present study, the expression frequency of HLA-C2(Lys80)+2DL1 was 27.27%, HLA-C1(Asn80)+2DL2/2DL3 was 68.83%, 2DS2+HLA-C1(Asn80) was 9.74% and 2DS1+HLA-C2(Lys80) was 9.74%. Of the individuals in the study, 72.08% expressed only KIR2DL1 without HLA-Cw, 21.43% expressed only KIR2DS1 without HLA-Cw(Lys)-KIR2DL1 and 2.60% expressed only KIR2DS2 without HLA-Cw(Asn)-KIR2DL2/L3. In conclusion, the expression of inhibitory HLA-Cw-KIR is higher than the expression of activating HLA-Cw-KIR and approximately 20% of the individuals separately expressed the activated HLA-Cw-KIR in the Jilin Han population in the present study.Entities:
Year: 2012 PMID: 23251287 PMCID: PMC3524289 DOI: 10.3892/etm.2012.763
Source DB: PubMed Journal: Exp Ther Med ISSN: 1792-0981 Impact factor: 2.447
Primers used for KIR genotyping by PCR-SSP.
| Gene | Primer | Sequence | Primer | Sequence | Size (bp) |
|---|---|---|---|---|---|
| 2DL1 | F1 | GTTGGTCAGATGTCATGTTTGAA | R1 | GGTCCCTGCCAGGTCTTGCG | 146 |
| F2 | TGGACCAAGAGTCTGCAGGA | R2 | TGTTGTCTCCCTAGAAGACG | 330 | |
| 2DL2 | F1 | CTGGCCCACCCAGGTCG | R1 | GGACCGATGGAGAAGTTGGCT | 173 |
| F2 | GAGGGGGAGGCCCATGAAT | R2 | TCGAGTTTGACCACTCGTAT | 151 | |
| 2DL3 | F1 | CTTCATCGCTGGTGCTG | R1 | AGGCTCTTGGTCCATTACAA | 550 |
| F2 | TCCTTCATCGCTGGTGCTG | R2 | GGCAGGAGACAACTTTGGATCA | 800 | |
| 2DL4 | F1 | CAGGACAAGCCCTTCTGC | R1 | CTGGGTGCCGACCACT | 254 |
| F2 | ACCTTCGCTTACAGCCCG | R2 | CCTCACCTGTGACAGAAACAG | 288 | |
| 2DS2 | F1 | TTCTGCACAGAGAGGGGAAGTA | R1 | GGGTCACTGGGAGCTGACAA | 175 |
| F2 | CGGGCCCCACGGTTT | R2 | GGTCACTCGAGTTTGACCACTCA | 240 | |
| 2DS3 | F1 | TGGCCCACCCAGGTCG | R1 | TGAAAACTGATAGGGGGAGTGAGG | 242 |
| F2 | CATTGACATGTACCATCTATCCAC | R2 | AAGCAGTGGGTCACTTGAC | 190 | |
| 2DS5 | F1 | TGATGGGGTCTCCAAGGG | R1 | TCCAGAGGGTCACTGGGC | 126 |
| F2 | ACAGAGAGGGGACGTTTAACC | R2 | ATGTCCAGAGGGTCACTGGG | 178 | |
| 3DL1 | F1 | CGCTGTGGTGCCTCGA | R1 | GGTGTGAACCCCGACATG | 191 |
| F2 | CCCTGGTGAAATCAGGAGAGAG | R2 | TGTAGGTCCCTGCAAGGGCAA | 186 | |
| 3DL2 | F1 | CAAACCCTTCCTGTCTGCCC | R1 | GTGCCGACCACCCAGTGA | 211 |
| F2 | CCCATGAACGTAGGCTCCG | R2 | CACACGCAGGGCAGGG | 130 | |
| 3DS1 | F1 | AGCCTGCAGGGAACAGAAG | R1 | GCCTGACTGTGGTGCTCG | 300 |
| F2 | CCTGGTGAAATCAGGAGAGAG | R2 | GTCCCTGCAAGGGCAC | 180 | |
| 3DL3 | F1 | GTCAGGACAAGCCCTTCCTC | R1 | GAGTGTGGGTGTGAACTGCA | 232 |
| F2 | TTCTGCACAGAGAGGGGATCA | R2 | GAGCCGACAACTCATAGGGTA | 165 | |
| 2DL5 | F1 | GCGCTGTGGTGCCTCG | R1 | GACCACTCAATGGGGGAGC | 214 |
| F2 | TGCAGCTCCAGGAGCTCA | R2 | GGGTCTGACCACTCATAGGGT | 191 | |
| 2DP1 | F1 | GTCTGCCTGGCCCAGCT | R1 | GTGTGAACCCCGACATCTGTAC | 205 |
| F2 | CCATCGGTCCCATGATGG | R2 | CACTGGGAGCTGACAACTGATG | 89 | |
| 2DS1 | F1 | CTTCTCCATCAGTCGCATGAA | R1 | AGAGGGTCACTGGGAGCTGAC | 102 |
| F2 | CTTCTCCATCAGTCGCATGAG | ||||
| 2DS4 | F1 | CTGGCCCTCCCAGGTCA | R1 | TCTGTAGGTTCCTGCAAGGACAG | 204 |
| F2 | GTTCAGGCAGGAGAGAAT | R2 | GTTTGACCACTCGTAGGGAGC | 197/219 | |
| 3DP1 | F1 | GGTGTGGTAGGAGCCTTAG | R1 | GAAAACGGTGTTTCGGAATAC | 280 |
| F2 | CGTCACCCTCCCATGATGTA | 395 |
KIR, killer cell immunoglobulin-like receptor; F1/F2, forward primers; R1/R2, reverse primers.
Primers used for HLA-Cw genotyping by PCR-SSP.
| Forward primers
| Reverse primers
| ||||
|---|---|---|---|---|---|
| Gene | Primer | Sequence | Primer | Sequence | Size (bp) |
| HLA-C1Asn80 | F | GAGGTGCCCGCCCGGCGA | R | CGCGCAGGTTCCGCAGGC | 332 |
| HLA-C2Lys80 | F | GAGGTGCCCGCCCGGCGA | R | CGCGCAGTTTCCGCAGGT | 332 |
HLA-Cw, human leukocyte antigen-Cw; Asn, asparagine; Lys, lysine.
Figure 1KIR genotyping by PCR-SSP. Lanes 1-16, the PCR-SSP products of KIR2DL1, KIR2DL2, KIR2DL3, KIR2DL4, KIR2DL5, KIR3DL1, KIR3DL2, KIR3DL3, KIR2DS2, KIR2DS3, KIR2DS5, KIR3DS1, KIR2DP1, KIR2DS1 and KIR3DP1, respectively; M, Marker 2000; KIR, killer cell immunoglobulin-like receptor.
Figure 2HLA-Cw genotyping by PCR-SSP. M, Marker 2000; C1, PCR-SSP products of HLA-Cw1Asn; C2, PCR-SSP products of HLA-Cw2Lys; HLA-Cw, human leukocyte antigen-Cw.
Phenotype and genotype frequency of KIR and HLA-Cw in the Jilin Han population.
| Gene | Number | Phenotype frequency (%) | Genotype frequency |
|---|---|---|---|
| 2DL1 | 153 | 99.351 | 0.919 |
| 2DL2 | 21 | 13.636 | 0.071 |
| 2DL3 | 153 | 99.351 | 0.919 |
| 2DL4 | 154 | 100 | 1 |
| 2DL5 | 49 | 31.818 | 0.174 |
| 3DL1 | 143 | 92.857 | 0.733 |
| 3DL2 | 154 | 100 | 1 |
| 3DL3 | 154 | 100 | 1 |
| 2DS2 | 19 | 12.338 | 0.064 |
| 2DS3 | 18 | 11.688 | 0.06 |
| 2DS5 | 37 | 24.026 | 0.128 |
| 3DS1 | 43 | 27.922 | 0.151 |
| 2DP1 | 153 | 99.351 | 0.919 |
| 2DS1 | 48 | 31.169 | 0.17 |
| 3DP1*003 | 76 | 49.351 | 0.288 |
| 3DP1*001/002/004 | 153 | 99.351 | 0.919 |
| 2DS4*001/002 | 113 | 73.377 | 0.484 |
| 2DS4*003-007 | 72 | 46.753 | 0.27 |
| HLA-C1Asn80 | 123 | 79.87 | 0.551 |
| HLA-C2Lys80 | 43 | 27.922 | 0.151 |
KIR, killer cell immunoglobulin-like receptor; HLA-Cw, human leukocyte antigen-Cw; Asn, asparagine; Lys, lysine.
The combined frequencies of various compound KIR-HLA genetypes in the Jilin Han population.
| iKIR+HLA | Frequency (%) | sKIR+HLA | Frequency (%) |
|---|---|---|---|
| HLA-C1Asn80+2DL2/2DL3 | 68.83 | 2DS2+HLA-C1Asn80 | 9.74 |
| HLA-C2Lys80+2DL1 | 27.27 | 2DS1+HLA-C2Lys80 | 9.74 |
KIR, killer cell immunoglobulin-like receptor; iKIR, inhibitory KIR; sKir, stimulatory KIR; HLA, human leukocyte antigen; Asn, asparagine; Lys, lysine.